TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32039739
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation training in addition to care as usual (multidisciplinary obesity treatment)
Study: 32039739
Drug: Care as
Normalized name: TopCare Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care as usual (multidisciplinary obesity treatment)
Study: 32583907
Drug: Minesapride 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 10 mg/d
Study: 32583907
Drug: Minesapride 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 20 mg/d
Study: 32583907
Drug: Minesapride 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 40 mg/d
Study: 34455152
Drug: Bilateral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral continuous T8 ESP blocks with a programmed intermittent bolus regimen of 10 mL 0.2% ropivacaine every 3 h for 48 h (n=30)
Study: 34455152
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 400 μg (n=30)
Study: 32037195
Drug: Demcizumab (DLL4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody) combined with paclitaxel (2.5 mg/kg and 5 mg/kg doses); administered on days 1 and 15 for 3 cycles, followed by paclitaxel until unacceptable toxicity or disease progression.
Study: 34819150
Drug: Unilateral quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral quadratus lumborum block (QLB) with 0.375% bupivacaine 0.5 mL/kg (QLB group)
Study: 32191267
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab (protocol-guided treatment)
Study: 32191267
Drug: Switched drug
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched drug regimen
Study: 33943011
Drug: S +
Normalized name: K-Y Yours + Mine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S + POCT (surgery plus postoperative chemotherapy)
Study: 33744963
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole
Study: 37656441
Drug: Corticosteroid monotherapy
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid monotherapy
Study: 34181360
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg VLX-ER
Study: 34181360
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg VLX-ER
Study: 36263928
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/ml (Gla-300)
Study: 35840157
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg once weekly
Study: 33549193
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg or 90 mg every 12 weeks
Study: 34157675
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise snacking and tai chi snacking
Study: 32700217
Drug: TIME program
Normalized name: Return 10 TIME LOCK PROGRAM KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIME program (Telehealth-supported, Integrated care with CHWs, and MEdication-access)
Study: 34187117
Drug: EGCG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (2 tablets, 300 mg)
Study: 34927342
Drug: Subcision combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcision combined with poly-l-lactic acid (PLLA) threads
Study: 32919816
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (100,000 IU monthly)
Study: 35514231
Drug: Edelweiss extract
Normalized name: edelweiss root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edelweiss extract formulation
Study: 33478428
Drug: Weekly rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly rifapentine and isoniazid regimen (self-administered for 12 weeks)
Study: 33478428
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin and isoniazid regimen (self-administered for 12 weeks)
Study: 33478428
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (weekly rifapentine/isoniazid and daily rifampicin/isoniazid)
Study: 33552685
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab with platinum-based chemotherapy (PCT)
Study: 34102783
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid (prednisone) one week before and three weeks after operation
Study: 32277364
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of bentysrepinine (50-900 mg)
Study: 32277364
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of bentysrepinine (300 mg and 600 mg)
Study: 32277364
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of bentysrepinine (600 mg) in food-effect study
Study: 33691268
Drug: Bra prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bra prescription (wearing a prescribed bra every day for eight weeks)
Study: 33710261
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Schisandra chinensis Baillon extract (SCe) daily for 12 weeks
Study: 36307427
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide 250 mg/day
Study: 32092321
Drug: iNO 30
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iNO 30 μg/kg ideal body weight/h
Study: 33065955
Drug: IncobotulinumtoxinA (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (single-dose studies)
Study: 33065955
Drug: IncobotulinumtoxinA (repeat-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (repeat-dose studies)
Study: 33065955
Drug: Placebo (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single-dose studies)
Study: 36208242
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with antivirals (including recombinant interferon alpha-2b and CHOP therapy, zidovudine combined with CHOP therapy, CHOP regimen combined with interferon and zidovudine)
Study: 36208242
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CHOP therapy)
Study: 34684407
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of hydrolyzed pine nut oil (PNO-FFA)
Study: 34684407
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 g hydrolyzed pine nut oil and 3 g olive oil (PNO-OO)
Study: 34684407
Drug: Both oil
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oil treatments (PNO-FFA and PNO-OO)
Study: 33129990
Drug: Monthly digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly digital hospitalization surveys
Study: 34020123
Drug: Gait perturbation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait perturbation protocol (treadmill-based, 10-week therapy)
Study: 36317783
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of CIS43LS per kilogram
Study: 36317783
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of CIS43LS per kilogram
Study: 32457106
Drug: SUBA™-Itraconazole (S-ITZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUBA™-Itraconazole (S-ITZ) 2x65 mg TID for 3 days and once on day 4
Study: 32457106
Drug: SUBA™-Itraconazole (S-ITZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUBA™-Itraconazole (S-ITZ) 2x65 mg BID for 14 days and a last dose on day 15
Study: 32457106
Drug: Conventional Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Itraconazole (C-ITZ) 2x100 mg TID for 3 days and once on day 4
Study: 32457106
Drug: Conventional Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Itraconazole (C-ITZ) 2x100 mg BID for 14 days and a last dose on day 15
Study: 33386619
Drug: Forgiveness intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Forgiveness intervention (twice-a-week sessions for 4 months)
Study: 33011099
Drug: Lenabasum 1
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum 1 mg QD (Weeks 1–4)
Study: 33011099
Drug: Lenabasum 5
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum 5 mg QD (Weeks 1–4)
Study: 33011099
Drug: Lenabasum 20
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum 20 mg QD (Weeks 5–12)
Study: 33011099
Drug: Lenabasum 20
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum 20 mg BID (Weeks 5–12)
Study: 33609425
Drug: 9-week nurse-led
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-week nurse-led Internet-based cognitive behavioural therapy for insomnia (I-CBTI) with support
Study: 33814126
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix 0.25 mg/day)
Study: 34489288
Drug: Indonesia Drug
Normalized name: influenza A virus A/Indonesia/05/2005 (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP), a 12-week cognitive behavioural therapy (CBT) and motivational interviewing programme delivered via video-conferencing.
Study: 34489288
Drug: Indonesia Drug
Normalized name: influenza A virus A/Indonesia/05/2005 (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP)
Study: 33176842
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg daily for 104 weeks
Study: 32951733
Drug: Vaginal cream
Normalized name: VAGINAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cream containing aqueous extract of Achillea millefolium
Study: 32951733
Drug: Vaginal cream
Normalized name: VAGINAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cream clotrimazole 1%
Study: 33367487
Drug: Diabetes on
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes on no medication
Study: 33367487
Drug: Diabetes on
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes on non-insulin antidiabetic drugs
Study: 32191203
Drug: Assigned Evidence‐Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned Evidence‐Based Medicine (EBM) articles and Rosh Review questions
Study: 32921117
Drug: Carbohydrate administration
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate administration 3 hours before surgery
Study: 35177019
Drug: ACORN intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACORN intervention + Treatment as usual (TAU)
Study: 33368937
Drug: Heat-patch treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-patch treatment
Study: 36131308
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of local anaesthetic
Study: 34099033
Drug: Group skills
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group skills treatment (stepped-care structured psychological group treatment)
Study: 34403658
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg + TCS
Study: 34403658
Drug: upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 30 mg + TCS
Study: 32626889
Drug: Oral implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral implant restoration (experimental group)
Study: 34638190
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral ESPB with 20 ml of 0.375% ropivacaine (group E)
Study: 34251097
Drug: Phenazopyridine 200
Normalized name: phenazopyridine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine 200 mg 3 times a day for 2 days and fosfomycin trometamol 3 g once
Study: 34251097
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol 3 g once and drotaverin 80 mg 3 times a day for 2 days
Study: 33384390
Drug: Dose-escalated adaptive
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated adaptive tumour‐focused radiotherapy (DART)
Study: 33384390
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose adaptive tumour‐focused radiotherapy
Study: 34915528
Drug: 16 G
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 G biopsy needle (Bard MC l616)
Study: 34915528
Drug: 18 G
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 G biopsy needle (Bard MC l820)
Study: 33879663
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement therapy (ONS)
Study: 33380582
Drug: 2-week continuous
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week continuous supplementation of hydrogen-rich water (HW), 500 mL daily on weekdays (total 5 L)
Study: 33380582
Drug: Single intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of hydrogen-rich water (HW), 500 mL
Study: 34170943
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid administration (clear fluids 0.75-1.0 times the volume of blood lost)
Study: 34170943
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration (clear fluids 1.5-2.0 times the volume of blood lost)
Study: 34170943
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid administration
Study: 34170943
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration
Study: 36185576
Drug: Routine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine intervention and chemotherapy
Study: 33146667
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (psilocybin therapy)
Study: 33146667
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (waiting list control)
Study: 34187621
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g transgenic rice
Study: 34187621
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g transgenic rice
Study: 32572719
Drug: OMDI 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMDI 0.002% (one drop once daily for 4 weeks)
Study: 34997525
Drug: Didactic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didactic preparation methods (various formats)
Study: 33090294
Drug: Evolocumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab therapy
Study: 33090294
Drug: Evolocumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab therapy in MI patients with uncontrolled familial hypercholesterolemia (FH)
Study: 32633141
Drug: Drug adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug adjusted control
Study: 35895759
Drug: 7.2% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% hypertonic saline solution (HS)
Study: 35895759
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline solution (IS)
Study: 33342710
Drug: Rapid titration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid titration protocols (target dose of 400 mg/day within 1 week)
Study: 33342710
Drug: Conventional weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional weekly titration protocol (target dose of 400 mg/day in three weeks)
Study: 33461602
Drug: Inhaled magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial diluted with 50 cc distilled water, nebulized via a mask) every eight hours for five days, in addition to standard treatment for COVID-19.
Study: 33461602
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COVID-19 only.
Study: 36526794
Drug: Ketorolac (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (0.5 mg/kg)
Study: 32393370
Drug: Paracetamol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (10 mg/kg)
Study: 36322461
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (sterile saline at room temperature)
Study: 32940751
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg intravenous methylprednisolone (study group)
Study: 32940751
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group)
Study: 32858399
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (4 g heptahydrate, infused over 30 min)
Study: 32698894
Drug: Dental Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental Health Component (DHC) of the Index of Orthodontic Treatment Need (IOTN)
Study: 32698894
Drug: Aesthetic Component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aesthetic Component (AC) of the Index of Orthodontic Treatment Need (IOTN)
Study: 33513879
Drug: B12 supplementation
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B12 supplementation (methylcobalamin) 1000 μg/day for one year
Study: 35836102
Drug: peg‐IFN‐α‐2b combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN‐α‐2b combined with TDF, GM‐CSF, and hepatitis B vaccine
Study: 34565664
Drug: Multisite stereotactic
Normalized name: polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisite stereotactic radiation therapy (SBRT) alone
Study: 33492696
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block (placebo injection)
Study: 34403081
Drug: 5-hydroxytryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (50 mg daily)
Study: 35050954
Drug: Drama therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drama therapy for 8 weeks
Study: 35050954
Drug: Drama therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drama therapy for 12 weeks
Study: 36573450
Drug: Cilofexor (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor (10 to 300 mg fasting or fed, 15 and 50 mg twice-daily fed)
Study: 36573450
Drug: Cilofexor (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor (doses >30 mg)
Study: 33172506
Drug: OMNI (animal-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMNI (animal-derived protein diet; n=9; 1.8 g/kg body mass per day)
Study: 33172506
Drug: VEG (vegan
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEG (vegan protein diet; n=10; mycoprotein providing 57% of daily protein intake; 1.8 g/kg body mass per day)
Study: 32439253
Drug: TelePR programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: TelePR programme (3 weekly training sessions, performance data sent through an app)
Study: 32161055
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with ambrisentan plus tadalafil (COMB)
Study: 32161055
Drug: Monotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy of either ambrisentan or tadalafil (MONO)
Study: 33080017
Drug: Tocilizumab (TCZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (TCZ), 8 mg/kg intravenously plus usual care on day 1 and on day 3 if clinically indicated.
Study: 33080017
Drug: Tocilizumab (TCZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (TCZ), 8 mg/kg intravenously plus usual care.
Study: 36123717
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy with patient’s musical preference at 60 dB
Study: 33516014
Drug: Dried citrus
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried citrus pulp (DCP) at 150 g/kg
Study: 33516014
Drug: Grape pomace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape pomace (DGP) at 150 g/kg
Study: 36555933
Drug: Rituximab 500
Normalized name: riTUXimab 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 500 mg
Study: 36555933
Drug: Rituximab 1000
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000 mg
Study: 34472200
Drug: 5‐mg flunarizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg flunarizine hydrochloride capsules (test)